Drug Discovery & Development - March 10, 2011
LAKE FOREST, Ill. (AP) - Drug and medical device maker Hospira Inc. said the Food and Drug Administration approved the company's generic version of Sanofi-Aventis' blockbuster cancer drug Taxotere.
The company said its generic Taxotere, or docetaxel, is a single-vial formulation as opposed to the two-step process for the branded Taxotere.
Hospira said Taxotere, which is approved to treat breast, lung, and other types of cancer, had U.S. sales of about $1.2 billion in 2010. It lost patent protection in November, opening the market up to generic competitors.
Shares of Hospira have traded between $48.69 and $60.49 over the last 52 weeks.
Date: March 9, 2011
Source: Associated Press
The company said its generic Taxotere, or docetaxel, is a single-vial formulation as opposed to the two-step process for the branded Taxotere.
Hospira said Taxotere, which is approved to treat breast, lung, and other types of cancer, had U.S. sales of about $1.2 billion in 2010. It lost patent protection in November, opening the market up to generic competitors.
Shares of Hospira have traded between $48.69 and $60.49 over the last 52 weeks.
Date: March 9, 2011
Source: Associated Press
No hay comentarios:
Publicar un comentario